Patents by Inventor Erin L. Filbert

Erin L. Filbert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TNFR2 ANTIBODIES AND METHODS OF USE
    Publication number: 20220372154
    Abstract: Provided are anti-tumor necrosis factor receptor 2 (TNFR2) antibodies and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of oncological diseases, inflammatory and/or autoimmune diseases, and others. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, does not substantially bind to TNFR1, herpesvirus entry mediator (HVEM), CD40, death receptor 6 (DR6), and/or osteoprotegerin (OPG).
    Type: Application
    Filed: September 11, 2020
    Publication date: November 24, 2022
    Inventors: Erin L. FILBERT, Sushma KRISHNAN, Christine TAN, Rena BAHJAT, Xiaodong YANG, Ryan ALVARADO
  • ANTI-VISTA ANTIBODIES AND METHODS OF USE
    Publication number: 20210139589
    Abstract: Provided are anti-VISTA monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of inflammatory, oncological, and infectious diseases.
    Type: Application
    Filed: June 22, 2018
    Publication date: May 13, 2021
    Inventors: Erin L. Filbert, Christine TAN, Pia BJÖRCK, Xiaodong YANG
  • ANTI-CD40 ANTIBODIES IN COMBINATION AND METHODS OF USE
    Publication number: 20210139594
    Abstract: The present invention provides methods that utilize an agonistic anti-CD40 antibody in combination with another immune modulating agent, such as an immune checkpoint inhibitor (e.g., PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, or VISTA inhibitor) and/or an innate immunity activator (e.g., TLR-4 agonist) and related compositions. The high affinity anti-CD40 antibody combinations may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases. In particular, combinations of the anti-CD40 antibody APX005M with an immune checkpoint inhibitor or an innate immunity activator are disclosed.
    Type: Application
    Filed: June 23, 2020
    Publication date: May 13, 2021
    Inventors: Pia Björck, Erin L. Filbert, Xiaodong Yang
  • ANTI-CD40 ANTIBODIES IN COMBINATION AND METHODS OF USE
    Publication number: 20180327496
    Abstract: The present invention provides methods that utilize an agonistic anti-CD40 antibody in combination with another immune modulating agent, such as an immune checkpoint inhibitor (e.g., PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, or VISTA inhibitor) and/or an innate immunity activator (e.g., TLR-4 agonist) and related compositions. The high affinity anti-CD40 antibody combinations may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases. In particular, combinations of the anti-CD40 antibody APX005M with an immune checkpoint inhibitor or an innate immunity activator are disclosed.
    Type: Application
    Filed: November 2, 2017
    Publication date: November 15, 2018
    Inventors: Pia Björck, Erin L. Filbert, Xiaodong Yang